Literature DB >> 6420108

The importance of urinary immunoglobulin light chain isoelectric point (pI) in nephrotoxicity in multiple myeloma.

R A Coward, I W Delamore, N P Mallick, E L Robinson.   

Abstract

There is clinical and experimental evidence to imply that urinary immunoglobulin light chains are nephrotoxic yet some patients pass large amounts for years with little renal damage. Animal experiments suggest that a light chain is more nephrotoxic if it has a high isoelectric point (i.e. is cationic in relation to urine pH). We studied 23 patients with multiple myeloma, measuring light chain excretion rate, light chain isoelectric point (pI) and creatinine clearance. Light chain excretion rate was independent of light chain isoelectric point and did not correlate with creatinine clearance. Light chain isoelectric point correlated with creatinine clearance, suggesting that this characteristic may be an important determinant of the nephrotoxic effect of these immunoglobulin constituents.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6420108     DOI: 10.1042/cs0660229

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  10 in total

1.  Isoelectric points of urinary light chains in myelomatosis: analysis in relation to nephrotoxicity.

Authors:  E A Johns; R Turner; E H Cooper; I C Maclennan
Journal:  J Clin Pathol       Date:  1986-08       Impact factor: 3.411

2.  The kidney in myeloma.

Authors:  T J Hamblin
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-04

3.  Light chains and the kidney.

Authors:  J R Bradley; S Thiru; D B Evans
Journal:  J Clin Pathol       Date:  1987-01       Impact factor: 3.411

4.  Renal impairment in myeloma: negative association with isoelectric point of excreted Bence-Jones protein.

Authors:  A G Norden; F V Flynn; L M Fulcher; J D Richards
Journal:  J Clin Pathol       Date:  1989-01       Impact factor: 3.411

5.  Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo.

Authors:  P W Sanders; G A Herrera; A Chen; B B Booker; J H Galla
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

6.  Electrophoretic study of the physico-chemical characteristics of Bence-Jones proteinuria and its association with kidney damage.

Authors:  M C Diemert; L Musset; O Gaillard; S Escolano; A Baumelou; F Rousselet; J Galli
Journal:  J Clin Pathol       Date:  1994-12       Impact factor: 3.411

7.  Renal replacement therapy in multiple myeloma and systemic amyloidosis.

Authors:  J H Brown; A P Maxwell; I Bruce; B G Murphy; C C Doherty
Journal:  Ir J Med Sci       Date:  1993-06       Impact factor: 1.568

Review 8.  Renal replacement therapy in multiple myeloma and systemic amyloidosis.

Authors:  J H Brown; C C Doherty
Journal:  Postgrad Med J       Date:  1993-09       Impact factor: 2.401

9.  High-dose intravenous melphalan in a patient with multiple myeloma and oliguric renal failure.

Authors:  M Pecherstorfer; I Zimmer-Roth; S Weidinger; K Irsigler; W M Halbmayer; W Ulrich; M Fischer; G Baumgartner
Journal:  Clin Investig       Date:  1994-07

10.  Reversibility of acute renal failure in elderly patients with the nephrotic syndrome.

Authors:  M Searle; C Cooper; J Elliman; R Dathan; A Maciver
Journal:  Postgrad Med J       Date:  1985-08       Impact factor: 2.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.